Under 10% of patients that would benefit from obesity jabs like Wegovy have access to them, states the global health agency as it releases its initial advice on the drugs.
Given in excess of 1,000,000,000 individuals worldwide now obese, it is advocating for increased and just access to this class of drugs.
Per estimates, more than two billion could be obese by 2030 unless action is taken.
"The latest guidance acknowledges that obesity is a long-term condition that can be managed with thorough and lifelong support," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are major obstacles to broad availability to the treatments that can help people shift substantial body mass, explains the body.
Skinny Jab Shortage
Even under the present most favorable outlook, the supply of these medications might only reach approximately 100 million people – less than 10% of eligible patients, according to the WHO.
The guideline calls on governments and firms to expand availability, via measures like voluntary licensing.
The intellectual property rights on the active ingredient – the main ingredient of Novo Nordisk's Wegovy – is scheduled to end in multiple countries in 2026.
The Way Weight-Loss Injections Operate
GLP-1 drugs mimick a biological compound to reduce digestion speed, suppress the appetite and enhance feelings of fullness so users eat less.
Individuals typically start to lose weight within a few weeks of commencing the regular doses.
Evidence suggests people may see weight return a year later of halting the treatment, when their normal appetite come back.
Being carrying excess weight increases your likelihood for developing health problems, like type 2 diabetes, cardiovascular issues, brain attack, and some malignancies.
Obesity concerns people in every country and was associated with 3.7 million fatalities worldwide in 2024, per the WHO.
